Associate Principal Scientist
Merck & Co., Inc.
Erik completed his PhD in Chemical and Biomolecular Engineering at the University of Delaware under the advice of Dr. Millicent Sullivan. Erik’s research focused on the design and characterization novel histone-mimetic biomaterials to enhance gene delivery and expression of growth factors for regenerative medicine applications. He also developed a mechanistic understanding of intracellular trafficking routes that direct nuclear gene transfer to guide the design of more effective polymeric gene delivery systems. Prior to his PhD, Erik obtained his B.S. in Chemical Engineering from Rensselaer Polytechnic Institute, Troy, NY. As a member of the Discovery Pharmaceutical Sciences Team at Merck & Co., Erik develops pharmaceutical formulations to advance drug-delivery technology in support of immunology and oncology therapeutic areas. His analysis of the physiochemical props of preclinical drug candidates functions to facilitiate downstream development for a wide variety of modalities (small molecules, peptides, biologics, etc.).